ImmunoGen, Inc.: valuation
What the market value assumes, and what the company's own statements and its peers' prices would put it at. Every assumption is yours to change.
Cash-flow value
The newest statements on file are more than two years old.
Your own DCF model
A full discounted-cash-flow model of ImmunoGen, Inc., started from its filings: revenue growth and margins year by year, bear, base and bull cases, the WACC and its parts, sensitivity tables and a value per share against the dated market price. Save it, share it with your team or by a read-only link.
Open the DCF modelAgainst its own history
ImmunoGen, Inc.'s multiples at each month end with a market cap on file, Jan 2020 to Jan 2024, each against its own median.
Price to sales
75.8×Now above its median of 15.0×, in the top quarter of its range; range 11.6× to 75.8× over 6 months.
as of Jan 5, 2024. Market caps: the dated values on file since 2020. Each month divides by the last twelve months' results that had been published by then (a quarter 45 days after it ended, a fiscal year 60 days after), so the past is not read with figures that came out later; months with a loss give no P/E. Newest month: Jan 5, 2024.
The statements it starts from
USD millions at each year's exchange rate; free cash flow = cash from operations less capital spending.
| Fiscal year | Revenue | Net income | Cash from operations | Capital spending | Free cash flow | Net debt | Source |
|---|---|---|---|---|---|---|---|
| FY2022to Dec 31, 2022 | $109 M | $-223 M | $-230 M | $1 M | $-231 M | — | SEC annual report (10-K, 20-F) |
| FY2021to Dec 31, 2021 | $70 M | $-139 M | $-169 M | $1 M | $-171 M | — | SEC annual report (10-K, 20-F) |
| FY2020to Dec 31, 2020 | $132 M | $-44 M | $-79 M | $1 M | $-80 M | — | SEC annual report (10-K, 20-F) |
| FY2019to Dec 31, 2019 | $82 M | $-104 M | $-88 M | $3 M | $-91 M | — | SEC annual report (10-K, 20-F) |
| FY2018to Dec 31, 2018 | $53 M | $-169 M | $-166 M | $5 M | $-172 M | — | SEC annual report (10-K, 20-F) |
| FY2017to Dec 31, 2017 | $115 M | $-96 M | $8 M | $1 M | $7 M | — | SEC annual report (10-K, 20-F) |
Each figure as filed; the full statements with every line and its filing are on the company page. Market value not on file.
How it is worked out: the cash-flow value is free cash flow grown at the first-stage rate for the years chosen, then at the long-run rate for ever, each year discounted at the risk-free rate plus the equity risk premium, less net debt. What the price assumes is the first-stage growth that makes that value equal today's market value. The starting cash flow, growth and net debt come from the statements; the risk-free rate from the US Treasury; the premium and the long-run growth are assumptions and are labelled so. This is arithmetic on reported figures, not advice.